Biostock reports in a new article about Chordate’s ongoing rights issue, the market establishment of Ozilia, and the exit strategy.
“The company’s strategy is expected to build up the value of its operations ahead of a successful sale to a larger player. The strategy is based on the overarching trend in the medtech and pharmaceutical market, where major players acquire smaller companies that have demonstrated proof-of-concept and market potential instead of conducting early-stage product development in-house. In recent years, many major players have invested in neurostimulation, which is the area in which Chordate Medical operates,” writes Biostock.
Read the full article (In Swedish)
